Cold Genesys looks to China for a $10M cash infusion

Damian Garde Immuno-oncology biotech Cold Genesys raised a $ 10 million B round, rallying a stable of Chinese financiers as it moves forward with a late-stage cancer therapy. FierceBiotech ...

Amarin wins injunction against FDA in free speech case

Eric Palmer On Friday, Amarin won what was being called a First Amendment free speech victory for drugmakers. It got a federal court to say the FDA cannot bar Amarin from discussing ...

Eyeing first profits, Tillman Gerngross’s Avitide nabs one last VC round

John Carroll When serial biotech entrepreneur and Dartmouth scientist Tillman Gerngross co-founded Avitide in early 2013, he had some specific ideas on how to quickly capitalize on ...

Perrigo CEO: Think Mylan’s buyout will come easily? Think again

Carly Helfand Perrigo has stayed quiet since Teva dropped its hostile pursuit of Mylan, choosing instead to snap up Allergan's generics business for $ 40.5 billion. Mylan's ...

Novo Nordisk launches diabetes ‘dream team’ contest with NBA star as a prize

Carly Helfand Former NBA star Dominique Wilkins is not just a spokesman for Novo Nordisk's Victoza. He's also a prize in a Type 2 diabetes sweepstakes the drugmaker is rolling ...

Cannabis patch startup pulls off a $42M IPO to fund drugs for epilepsy, pain

Damian Garde Pennsylvania drugmaker Zynerba Pharmaceuticals is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $ 42 ...

With $300M spent on potential split, Pfizer CEO now ‘biased’ toward branded M&A

Tracy Staton Now that Hospira's in the bag, Pfizer execs have less of an appetite for M&A in their Established Products unit. That $ 16 billion deal gives Pfizer added heft ...

AstraZeneca ties up with little Mirati on another PD-L1 combo trial

John Carroll AstraZeneca's big MedImmune subsidiary has a new partner for its closely-watched PD-L1 checkpoint inhibitor durvalumab (MEDI4736). Little Mirati Therapeutics, which ...

Celgene buys into GlobeImmune’s cancer immunotherapy

Damian Garde GlobeImmune, reeling from a costly clinical failure, secured a commitment from long-time partner Celgene to collaborate on a new cancer immunotherapy. FierceBiotech News

With more consolidation on tap in generics, who’s next to buy and be bought?

Carly Helfand FiercePharma News

Baxalta to Shire: We’re young, we’re just starting to grow, and we’re rejecting your buyout offer

Carly Helfand On Tuesday, Shire went public with a $ 30 billion bid for Baxalta that had already been rejected once. And the second time around, Baxalta had the same answer: It's ...

Baxalta responds to a frustrated Shire: The answer is still ‘no’

John Carroll Baxalta execs didn't like the idea of a $ 30 billion all-share Shire buyout when they heard it the first time on July 10–and they didn't warm to it at all ...
Page 5 of 6« First...23456
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS